Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including HCC. However, a considerable proportion of pat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-06, Vol.7 (23), p.34988-35000
Hauptverfasser:	Vandewynckel, Yves-Paul, Coucke, Céline, Laukens, Debby, Devisscher, Lindsey, Paridaens, Annelies, Bogaerts, Eliene, Vandierendonck, Astrid, Raevens, Sarah, Verhelst, Xavier, Van Steenkiste, Christophe, Libbrecht, Louis, Geerts, Anja, Van Vlierberghe, Hans
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - pharmacology Carcinoma, Hepatocellular - drug therapy Cell Proliferation - drug effects Cell Survival - drug effects Cinnamates - pharmacology Drug Synergism Endoplasmic Reticulum Stress - drug effects Humans Liver Neoplasms - drug therapy Mice Nelfinavir - pharmacology Oligopeptides - pharmacology Proteasome Inhibitors - pharmacology Research Paper Thiourea - analogs & derivatives Thiourea - pharmacology Tunicamycin - pharmacology Unfolded Protein Response - drug effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!